Bigelow Investment Advisors LLC raised its stake in iShares Biotechnology ETF (NASDAQ:IBB – Free Report) by 73.9% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 4,053 shares of the financial services provider’s stock after purchasing an additional 1,722 shares during the quarter. Bigelow Investment Advisors LLC’s holdings in iShares Biotechnology ETF were worth $551,000 at the end of the most recent quarter.
A number of other hedge funds and other institutional investors also recently modified their holdings of the stock. Vontobel Holding Ltd. grew its holdings in iShares Biotechnology ETF by 9.5% during the 1st quarter. Vontobel Holding Ltd. now owns 5,060 shares of the financial services provider’s stock valued at $659,000 after purchasing an additional 440 shares in the last quarter. Blair William & Co. IL increased its position in shares of iShares Biotechnology ETF by 9.7% during the first quarter. Blair William & Co. IL now owns 18,717 shares of the financial services provider’s stock worth $2,439,000 after acquiring an additional 1,659 shares during the last quarter. NewEdge Advisors LLC boosted its holdings in iShares Biotechnology ETF by 11.7% in the first quarter. NewEdge Advisors LLC now owns 13,777 shares of the financial services provider’s stock valued at $1,796,000 after purchasing an additional 1,445 shares during the last quarter. DCF Advisers LLC acquired a new stake in iShares Biotechnology ETF during the 1st quarter valued at approximately $912,000. Finally, Laurel Wealth Advisors Inc. increased its holdings in iShares Biotechnology ETF by 22.6% during the 1st quarter. Laurel Wealth Advisors Inc. now owns 3,019 shares of the financial services provider’s stock worth $393,000 after purchasing an additional 557 shares during the last quarter. Institutional investors and hedge funds own 62.45% of the company’s stock.
iShares Biotechnology ETF Price Performance
Shares of IBB traded up $0.08 during midday trading on Friday, hitting $124.72. The company had a trading volume of 1,996,612 shares, compared to its average volume of 1,809,704. The company’s 50 day moving average price is $135.29 and its 200 day moving average price is $129.51. iShares Biotechnology ETF has a 52 week low of $111.83 and a 52 week high of $141.16.
iShares Biotechnology ETF Announces Dividend
iShares Biotechnology ETF Profile
iShares Nasdaq Biotechnology ETF (the Fund), formerly iShares Nasdaq Biotechnology Index Fund, is an exchange-traded fund (ETF). The Fund seeks investment results that correspond generally to the price and yield performance of the NASDAQ Biotechnology Index (the Index). The Index contains securities of NASDAQ listed companies that are classified according to the Industry Classification Benchmark as either biotechnology or pharmaceuticals, which also meet other eligibility criteria determined by NASDAQ.
Further Reading
- Five stocks we like better than iShares Biotechnology ETF
- Stock Ratings and Recommendations: Understanding Analyst Ratings
- Comprehensive Analysis of PayPal Stock
- How to Invest in Small Cap StocksÂ
- Intuitive Surgical Stock Can Trend Much Higher This YearÂ
- The Role Economic Reports Play in a Successful Investment Strategy
- Alibaba Stock Analysis: Insights, Trends, and Future Predictions
Want to see what other hedge funds are holding IBB? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for iShares Biotechnology ETF (NASDAQ:IBB – Free Report).
Receive News & Ratings for iShares Biotechnology ETF Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for iShares Biotechnology ETF and related companies with MarketBeat.com's FREE daily email newsletter.